Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$948.01 -26.95 (-2.76%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$950.10 +2.09 (+0.22%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The company has demonstrated significant revenue growth, with a recent quarterly revenue increase of over 55% compared to the same period last year, indicating strong market demand for its products.
  • Eli Lilly and Co has set ambitious earnings per share (EPS) guidance for FY 2026, projecting between 35.500 and 37.000 EPS, which suggests confidence in future profitability.
  • Recent analyst upgrades have raised the price target for Eli Lilly and Co shares, with estimates now reaching around $1,283, reflecting positive sentiment and potential for stock appreciation.

Cons of Eli Lilly and Company

  • Despite the positive growth, there is a risk of market volatility that could impact stock performance, especially in the pharmaceutical sector where regulatory changes can affect operations.
  • One analyst has issued a "Sell" rating, indicating that not all market experts are confident in the stock's future performance, which could lead to potential declines.
  • Competition in the pharmaceutical industry is fierce, and new entrants could challenge Eli Lilly and Co's market share, potentially affecting future revenue growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$918.16 billion
P/E Ratio
33.68
Consensus Rating
Moderate Buy
Consensus Price Target
$1,218.33 (+28.5% Upside)
Volume
3.24 million shares
Average Volume
3.39 million shares
Today's Range
$947.51
$980.00
50-Day Range
$851.65
$1,050.39
52-Week Range
$623.78
$1,133.95
Dividend Yield
0.71%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$221.17 -1.34 (-0.60%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$221.25 +0.08 (+0.04%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $227.51, which may present a buying opportunity for investors looking for value in a well-established company.
  • Johnson & Johnson has received multiple upgrades from analysts, with price targets raised to as high as $280.00, indicating strong market confidence in the company's future performance.
  • The company has a solid market capitalization of approximately $547.66 billion, reflecting its stability and significant presence in the healthcare sector.

Cons of Johnson & Johnson

  • Market trends have shifted towards technology and growth sectors, which may divert capital away from defensive stocks like Johnson & Johnson, potentially leading to selling pressure.
  • Insider ownership is relatively low, with only 0.16% of the stock held by corporate insiders, which may raise concerns about alignment between management and shareholder interests.
  • Recent insider sales, while not necessarily negative, could indicate that executives are taking profits, which might suggest a lack of confidence in short-term stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$535.63 billion
P/E Ratio
25.57
Consensus Rating
Moderate Buy
Consensus Price Target
$252.48 (+14.2% Upside)
Volume
5.46 million shares
Average Volume
7.86 million shares
Today's Range
$220.92
$223.37
50-Day Range
$222.37
$248.81
52-Week Range
$146.12
$251.71
Dividend Yield
2.34%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$201.24 -1.47 (-0.73%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$201.24 +0.00 (+0.00%)
As of 05/8/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie has received multiple upgrades from analysts, with a recent "buy" rating and a price target set at $234.00, indicating strong confidence in the stock's potential for growth.
  • The stock is currently trading around $208.00, which is below its 52-week high of $244.81, suggesting potential for price appreciation as it approaches previous highs.
  • AbbVie has a solid market capitalization of approximately $367.78 billion, reflecting its stability and strong position in the pharmaceutical industry.

Cons of AbbVie

  • Recent insider selling, including significant transactions by executives, may raise concerns about the company's future prospects and could negatively impact investor sentiment.
  • AbbVie has faced challenges with pipeline trimming, including the discontinuation of a cancer candidate, which could affect future revenue streams and growth potential.
  • There have been small cuts to analyst estimates for future earnings, indicating that some analysts may be cautious about AbbVie's growth trajectory in the coming years.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$358.43 billion
P/E Ratio
99.13
Consensus Rating
Moderate Buy
Consensus Price Target
$252.90 (+25.7% Upside)
Volume
4.76 million shares
Average Volume
6.93 million shares
Today's Range
$200.02
$202.40
50-Day Range
$197.24
$235.90
52-Week Range
$176.57
$244.81
Dividend Yield
3.41%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$379.49 +9.75 (+2.64%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$379.32 -0.18 (-0.05%)
As of 05/8/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

Market Capitalization
$335.78 billion
P/E Ratio
28.66
Consensus Rating
Moderate Buy
Consensus Price Target
$378.88 (-0.2% Downside)
Volume
6.44 million shares
Average Volume
8.18 million shares
Today's Range
$371.99
$379.98
50-Day Range
$259.15
$371.07
52-Week Range
$234.60
$387.21
Dividend Yield
2.39%
Novartis stock logo

5. Novartis NYSE:NVS

$145.98 +0.59 (+0.41%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$146.20 +0.22 (+0.15%)
As of 05/8/2026 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $154, reflecting a stable market position and potential for growth.
  • Recent upgrades from multiple analysts, including a "buy" rating from Argus, indicate positive market sentiment and confidence in the company's future performance.
  • Novartis AG has reported strong earnings, with a recent EPS of $2.03, surpassing consensus estimates, showcasing its profitability and operational efficiency.

Cons of Novartis

  • Analysts have recently reduced their FY2027 earnings per share estimates, indicating potential challenges in meeting growth expectations.
  • Despite a strong market presence, the stock has experienced fluctuations, with a 52-week low of $104.93, suggesting volatility that could deter risk-averse investors.
  • Some analysts have issued "hold" ratings, reflecting uncertainty about the stock's short-term performance and potential for significant appreciation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$277.43 billion
P/E Ratio
20.91
Consensus Rating
Hold
Consensus Price Target
$141.20 (-3.3% Downside)
Volume
1.07 million shares
Average Volume
1.36 million shares
Today's Range
$145.48
$146.67
50-Day Range
$142.99
$168.61
52-Week Range
$104.93
$170.46
Dividend Yield
2.12%
Merck & Co., Inc. stock logo

6. Merck & Co., Inc. NYSE:MRK

$111.26 -1.05 (-0.93%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$111.84 +0.59 (+0.53%)
As of 05/8/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $111, which reflects a stable market position and potential for growth.
  • Merck has a strong market capitalization of approximately $275 billion, indicating a solid financial foundation and investor confidence.
  • Recent analyst upgrades suggest a positive outlook, with several firms raising their price targets, indicating potential for stock appreciation.

Cons of Merck & Co., Inc.

  • There are concerns about longer-term growth risks, particularly related to competitive threats to key products like Keytruda, which could impact future sales.
  • Recent quarterly losses due to charges related to product developments may raise concerns about the company's short-term profitability.
  • Market volatility and economic uncertainties could affect Merck's stock performance, making it a riskier investment in the current climate.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$277.36 billion
P/E Ratio
31.34
Consensus Rating
Moderate Buy
Consensus Price Target
$128.18 (+15.2% Upside)
Volume
5.71 million shares
Average Volume
9.56 million shares
Today's Range
$111.18
$113.01
50-Day Range
$109.33
$123.45
52-Week Range
$73.31
$125.14
Dividend Yield
3.03%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$46.02 +0.22 (+0.48%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$45.87 -0.15 (-0.33%)
As of 05/8/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Recent earnings estimates for FY2026 have been increased, indicating positive growth expectations, with analysts forecasting earnings per share of $3.22, slightly up from previous estimates.
  • The current stock price is around $45.78, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
  • Strong institutional interest is evident, with significant increases in stakes from major investment firms, suggesting confidence in the company's future performance.

Cons of Novo Nordisk A/S

  • Despite positive earnings forecasts, the consensus estimate for the current full-year earnings is slightly higher at $3.34 per share, indicating potential pressure on meeting or exceeding expectations.
  • Recent downgrades from several brokerages, including a shift from "buy" to "hold" ratings, may signal caution among analysts regarding the stock's short-term performance.
  • The stock has experienced fluctuations, with a 1-year low of $35.12 and a high of $81.44, suggesting volatility that could concern risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$204.50 billion
P/E Ratio
10.80
Consensus Rating
Hold
Consensus Price Target
$65.56 (+42.5% Upside)
Volume
11.99 million shares
Average Volume
18.72 million shares
Today's Range
$45.19
$46.14
50-Day Range
$35.28
$45.82
52-Week Range
$35.12
$81.44
Dividend Yield
3.82%
Amgen stock logo

8. Amgen NASDAQ:AMGN

$331.70 +2.61 (+0.79%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$331.99 +0.29 (+0.09%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $329, which reflects a strong market position and potential for growth.
  • Amgen Inc. reported earnings per share of $5.15, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a solid revenue growth of 5.8% compared to the same quarter last year, showcasing its ability to expand its market share.

Cons of Amgen

  • There is investor apprehension regarding Amgen's aggressive strategy in the obesity market, which may impact short-term profits.
  • The company's high debt-to-equity ratio of 5.65 suggests a reliance on debt financing, which can be risky in volatile markets.
  • Recent market commentary has framed the company's quarterly performance as "generally in-line," indicating a lack of significant growth momentum.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$177.61 billion
P/E Ratio
23.08
Consensus Rating
Hold
Consensus Price Target
$357.12 (+7.7% Upside)
Volume
1.76 million shares
Average Volume
2.66 million shares
Today's Range
$328.00
$332.33
50-Day Range
$328.91
$388.16
52-Week Range
$261.43
$391.29
Dividend Yield
3.06%
Thermo Fisher Scientific stock logo

9. Thermo Fisher Scientific NYSE:TMO

$464.64 -9.82 (-2.07%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$464.25 -0.39 (-0.08%)
As of 05/8/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $469, which reflects a strong market position and potential for growth.
  • Recent analyst upgrades indicate positive sentiment, with multiple firms issuing "buy" ratings and setting price targets above the current stock price, suggesting potential upside.
  • The company has a solid market capitalization of approximately $175 billion, indicating stability and investor confidence.

Cons of Thermo Fisher Scientific

  • Recent insider sales, while part of a planned strategy, may raise concerns about executives' confidence in the company's short-term performance.
  • The stock has experienced fluctuations, with a 12-month high of $643.99 and a low of $385.46, indicating volatility that could deter risk-averse investors.
  • Analysts have recently adjusted price targets downward, which may signal a cautious outlook on the company's near-term growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$176.32 billion
P/E Ratio
25.54
Consensus Rating
Buy
Consensus Price Target
$619.65 (+33.4% Upside)
Volume
3.89 million shares
Average Volume
2.13 million shares
Today's Range
$456.36
$473.49
50-Day Range
$463.99
$531.69
52-Week Range
$385.46
$643.99
Dividend Yield
0.40%
Gilead Sciences stock logo

10. Gilead Sciences NASDAQ:GILD

$131.33 -2.73 (-2.04%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$131.44 +0.11 (+0.08%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Market Capitalization
$166.40 billion
P/E Ratio
17.89
Consensus Rating
Moderate Buy
Consensus Price Target
$157.15 (+19.7% Upside)
Volume
10.25 million shares
Average Volume
5.78 million shares
Today's Range
$129.00
$133.34
50-Day Range
$127.75
$150.03
52-Week Range
$96.18
$157.29
Dividend Yield
2.45%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$450.06 -3.43 (-0.76%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$451.05 +0.99 (+0.22%)
As of 05/8/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The stock currently has an average price target of approximately $581.91, indicating potential upside from its current trading levels.
  • Intuitive Surgical, Inc. has received a majority of "Buy" ratings from analysts, suggesting strong confidence in the company's growth prospects.
  • The company is a leader in robotic-assisted surgical systems, particularly with its latest da Vinci surgical systems, which enhance precision and control in minimally invasive procedures.

Cons of Intuitive Surgical

  • Recent recalls of da Vinci instruments due to safety complaints could impact the company's reputation and revenue from service and consumables.
  • Increased competition in the surgical robotics market, particularly from companies like Johnson & Johnson, may pressure Intuitive Surgical's market share and pricing power.
  • Some analysts have lowered their price targets, indicating a cautious sentiment that could lead to increased volatility in the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$160.61 billion
P/E Ratio
54.55
Consensus Rating
Moderate Buy
Consensus Price Target
$581.91 (+29.3% Upside)
Volume
2.39 million shares
Average Volume
2.27 million shares
Today's Range
$447.00
$454.32
50-Day Range
$450.65
$506.88
52-Week Range
$427.84
$603.88
Dividend Yield
N/A
Abbott Laboratories stock logo

12. Abbott Laboratories NYSE:ABT

$84.24 -2.78 (-3.19%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$84.40 +0.16 (+0.19%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $115, reflecting a strong market position and investor confidence in the company's growth potential.
  • Abbott Laboratories recently reported quarterly earnings that exceeded analyst expectations, indicating robust financial health and operational efficiency.
  • The company has a solid dividend yield of approximately 2.8%, providing a steady income stream for investors.

Cons of Abbott Laboratories

  • The stock has seen target price reductions from several analysts, which may indicate concerns about future growth prospects.
  • Insider trading activity shows a slight decrease in ownership, which could signal a lack of confidence among executives.
  • The company's price-to-earnings ratio is relatively high, suggesting that the stock may be overvalued compared to its earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$151.56 billion
P/E Ratio
23.60
Consensus Rating
Moderate Buy
Consensus Price Target
$119.43 (+41.8% Upside)
Volume
10.89 million shares
Average Volume
14.16 million shares
Today's Range
$84.08
$87.31
50-Day Range
$86.25
$116.21
52-Week Range
$84.08
$139.06
Dividend Yield
2.90%
Pfizer stock logo

13. Pfizer NYSE:PFE

$25.65 -0.83 (-3.15%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$25.68 +0.03 (+0.11%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $40, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Pfizer Inc. has a strong market capitalization of approximately $152 billion, indicating a solid position in the industry and potential for growth.
  • The company reported a quarterly earnings per share (EPS) of $0.66, exceeding expectations, which reflects strong operational performance and profitability.

Cons of Pfizer

  • Competitive pressure from market leaders in obesity treatments, such as Novo Nordisk, may hinder Pfizer's growth prospects in this lucrative segment.
  • The company's revenue was down 1.2% year-over-year, indicating potential challenges in maintaining sales momentum.
  • With a debt-to-equity ratio of 0.71, there are concerns about the company's leverage and financial stability in a fluctuating market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$150.92 billion
P/E Ratio
19.58
Consensus Rating
Hold
Consensus Price Target
$28.74 (+12.0% Upside)
Volume
37.42 million shares
Average Volume
36.09 million shares
Today's Range
$25.60
$26.20
50-Day Range
$26.27
$28.56
52-Week Range
$21.97
$28.75
Dividend Yield
6.50%
Danaher stock logo

14. Danaher NYSE:DHR

$170.98 -4.68 (-2.66%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$171.21 +0.23 (+0.13%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $175, which may present a buying opportunity for investors looking for growth in the healthcare sector.
  • Danaher Co. has a strong institutional ownership, with over 79% of its stock held by institutional investors, indicating confidence in the company's future performance.
  • The company has shown significant growth in recent quarters, with institutional investors like CX Institutional increasing their stake by nearly 4,000% recently, reflecting strong market interest.

Cons of Danaher

  • The stock has experienced volatility, with a 52-week high of $242.80 and a low of $172.34, indicating potential risks associated with price fluctuations.
  • Despite strong institutional backing, insider selling has occurred, with executives like Gregory M. Milosevich reducing their holdings, which may signal concerns about the company's future performance.
  • The price-to-earnings ratio is relatively high at around 33.91, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$124.33 billion
P/E Ratio
33.07
Consensus Rating
Moderate Buy
Consensus Price Target
$240.70 (+40.8% Upside)
Volume
5.85 million shares
Average Volume
5.12 million shares
Today's Range
$170.74
$175.48
50-Day Range
$174.69
$210.28
52-Week Range
$170.74
$242.80
Dividend Yield
0.91%
Bristol Myers Squibb stock logo

15. Bristol Myers Squibb NYSE:BMY

$56.10 -0.15 (-0.27%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$56.21 +0.11 (+0.20%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $58, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Bristol-Myers Squibb has a strong portfolio of products, including recent advancements in oncology treatments like Opdualag for melanoma, which could drive future revenue growth.
  • The company reported a revenue increase of 2.6% compared to the same quarter last year, indicating a positive trend in sales performance.

Cons of Bristol Myers Squibb

  • Analysts have maintained a Hold rating, suggesting uncertainty about the company's ability to offset declines from legacy products.
  • The company faces challenges with the upcoming patent expiration of Eliquis, which could significantly impact revenue streams.
  • Despite recent revenue growth, the overall market sentiment remains cautious, which may affect stock performance in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$114.87 billion
P/E Ratio
15.76
Consensus Rating
Hold
Consensus Price Target
$61.31 (+9.3% Upside)
Volume
9.97 million shares
Average Volume
10.17 million shares
Today's Range
$55.78
$56.54
50-Day Range
$56.18
$62.39
52-Week Range
$42.52
$62.89
Dividend Yield
4.48%
Stryker stock logo

16. Stryker NYSE:SYK

$285.49 -8.74 (-2.97%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$287.80 +2.30 (+0.81%)
As of 05/8/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $292, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Stryker Co. has received multiple "overweight" ratings from analysts, indicating strong confidence in its future performance.
  • The company reported a revenue increase of 2.6% compared to the same quarter last year, showcasing its ability to grow even in challenging market conditions.

Cons of Stryker

  • The company recently missed earnings expectations, reporting $2.60 earnings per share, which was below the consensus estimate of $2.98, raising concerns about its short-term performance.
  • Analysts have adjusted their price targets downward, with UBS Group lowering its target from $400 to $380, indicating a more cautious outlook.
  • Insider selling activity has been noted, with a director selling a significant number of shares, which could signal a lack of confidence in the stock's near-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$112.69 billion
P/E Ratio
33.04
Consensus Rating
Moderate Buy
Consensus Price Target
$395.48 (+38.5% Upside)
Volume
2.12 million shares
Average Volume
2.37 million shares
Today's Range
$284.95
$294.91
50-Day Range
$292.13
$387.53
52-Week Range
$284.95
$404.87
Dividend Yield
1.20%
CVS Health stock logo

17. CVS Health NYSE:CVS

$90.50 +3.14 (+3.59%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$90.16 -0.33 (-0.37%)
As of 05/8/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. has recently revamped its loyalty program, which could enhance customer retention and drive sales growth.
  • Analysts have shown strong support for CVS Health Co., with a consensus rating of "Moderate Buy" and a target price around $95, indicating potential for stock appreciation.
  • The current stock price is approximately $81, which may present a buying opportunity for investors looking for value in the healthcare sector.

Cons of CVS Health

  • Analysts are predicting a decline in near-term earnings, which could negatively impact investor sentiment and stock performance.
  • Concerns about the company's ability to meet earnings expectations may limit upside potential, especially if margins are weaker than anticipated.
  • The company's high dividend payout ratio suggests that a significant portion of earnings is being returned to shareholders, which could limit reinvestment in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$111.47 billion
P/E Ratio
39.87
Consensus Rating
Moderate Buy
Consensus Price Target
$95.92 (+6.0% Upside)
Volume
11.14 million shares
Average Volume
7.81 million shares
Today's Range
$87.36
$90.89
50-Day Range
$69.98
$87.34
52-Week Range
$58.35
$90.89
Dividend Yield
3.04%
Vertex Pharmaceuticals stock logo

18. Vertex Pharmaceuticals NASDAQ:VRTX

$429.82 +4.82 (+1.13%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$428.50 -1.32 (-0.31%)
As of 05/8/2026 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $427.65, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Vertex Pharmaceuticals Incorporated has recently reported strong quarterly earnings, exceeding analysts' expectations with an EPS of $4.47, indicating robust financial health and operational efficiency.
  • Analysts have a consensus rating of "Moderate Buy" for Vertex Pharmaceuticals Incorporated, with multiple firms raising their price targets, suggesting positive market sentiment and potential for stock appreciation.

Cons of Vertex Pharmaceuticals

  • Insider selling has been observed, with corporate insiders selling over 80,000 shares valued at approximately $37.9 million in the last 90 days, which may raise concerns about the company's future prospects.
  • Despite strong earnings, the stock has experienced fluctuations, and the current price is significantly lower than its 52-week high of $507.92, indicating potential volatility.
  • Analysts have mixed ratings, with some firms downgrading their outlook, which could signal uncertainty about the company's future performance in a competitive market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$107.87 billion
P/E Ratio
25.49
Consensus Rating
Moderate Buy
Consensus Price Target
$555.17 (+29.2% Upside)
Volume
953,334 shares
Average Volume
1.10 million shares
Today's Range
$421.11
$431.94
50-Day Range
$423.24
$499.17
52-Week Range
$362.50
$507.92
Dividend Yield
N/A
Sanofi stock logo

19. Sanofi NASDAQ:SNY

$43.31 +0.13 (+0.30%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$43.45 +0.14 (+0.32%)
As of 05/8/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has recently increased its annual dividend to $2.4225, reflecting a strong commitment to returning value to shareholders, which can be attractive for income-focused investors.
  • The current stock price is around $44.55, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Analysts have issued a consensus target price of $62.67, suggesting potential upside for investors if the stock approaches this target.

Cons of Sanofi

  • Recent earnings estimates for FY2026 have been reduced to $4.92 per share, indicating potential challenges in meeting previous growth expectations.
  • Sanofi's stock has experienced fluctuations, with a 1-year low of $44.00, which may raise concerns about its stability and performance in the market.
  • Several analysts have downgraded their ratings on Sanofi, with a notable shift from "strong-buy" to "buy," suggesting a more cautious outlook on the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$105.32 billion
P/E Ratio
12.10
Consensus Rating
Hold
Consensus Price Target
$51.00 (+17.8% Upside)
Volume
2.52 million shares
Average Volume
2.65 million shares
Today's Range
$42.78
$43.31
50-Day Range
$43.18
$48.66
52-Week Range
$42.78
$53.36
Dividend Yield
4.04%
GSK stock logo

20. GSK NYSE:GSK

$50.38 -0.12 (-0.23%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$50.38 -0.01 (-0.01%)
As of 05/8/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • GSK plc is currently recognized as a momentum stock, attracting interest from long-term investors, which can lead to potential stock price appreciation.
  • The company recently announced a quarterly dividend of $0.44 per share, providing a yield of approximately 3.4%, which can be appealing for income-focused investors.
  • GSK plc's revenue has shown a year-over-year increase, indicating strong operational performance and growth potential in its pharmaceutical and healthcare segments.

Cons of GSK

  • GSK plc recently withdrew its application for leucovorin calcium, which could negatively impact investor sentiment and limit potential revenue from this product.
  • There has been a significant increase in short interest, indicating a rise in bearish sentiment among investors, which can lead to increased volatility in the stock price.
  • Market commentary suggests mixed views on GSK plc's valuation after a strong run, leading some investors to reassess the risk versus reward of holding the stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$102.47 billion
P/E Ratio
13.09
Consensus Rating
Reduce
Consensus Price Target
$53.00 (+5.2% Upside)
Volume
2.41 million shares
Average Volume
4.28 million shares
Today's Range
$50.05
$50.57
50-Day Range
$50.37
$59.54
52-Week Range
$35.45
$61.69
Dividend Yield
3.72%
Medtronic stock logo

21. Medtronic NYSE:MDT

$76.03 -1.93 (-2.47%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$76.23 +0.20 (+0.26%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The stock has a consensus target price of approximately $107.80, indicating potential for price appreciation from its current trading levels.
  • Medtronic plc has a strong market capitalization of over $105 billion, reflecting its significant presence and stability in the medical technology sector.
  • Recent analyst ratings show a mix of "buy" and "hold" recommendations, suggesting confidence in the company's future performance.

Cons of Medtronic

  • Insider ownership is relatively low at 0.26%, which may raise concerns about alignment between management and shareholder interests.
  • Recent stock performance has shown volatility, with the price fluctuating between a 52-week low of around $79.93 and a high of approximately $106.33.
  • Some analysts have downgraded their ratings, indicating potential caution regarding the company's short-term outlook.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$100.09 billion
P/E Ratio
21.18
Consensus Rating
Moderate Buy
Consensus Price Target
$107.80 (+41.8% Upside)
Volume
10.20 million shares
Average Volume
9.39 million shares
Today's Range
$75.91
$78.34
50-Day Range
$77.64
$98.09
52-Week Range
$75.91
$106.33
Dividend Yield
3.64%
HCA Healthcare stock logo

22. HCA Healthcare NYSE:HCA

$434.58 +5.56 (+1.30%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$435.15 +0.57 (+0.13%)
As of 05/8/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $430, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • HCA Healthcare, Inc. has shown resilience with a quarterly revenue increase of 4.3% year-over-year, indicating strong operational performance.
  • The company recently announced a quarterly dividend of $0.78, reflecting a commitment to returning value to shareholders, with an annualized yield of 0.7%.

Cons of HCA Healthcare

  • The company experienced a negative return on equity of 295.93%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Recent insider selling, with executives offloading shares, could signal a lack of confidence in the company's near-term performance.
  • The lapse in ACA subsidy funding has negatively impacted recent results, costing the company approximately $150 million in Q1, which could affect future earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$95.17 billion
P/E Ratio
14.94
Consensus Rating
Moderate Buy
Consensus Price Target
$517.82 (+19.2% Upside)
Volume
1.44 million shares
Average Volume
1.11 million shares
Today's Range
$431.42
$438.00
50-Day Range
$428.94
$545.88
52-Week Range
$330.00
$556.52
Dividend Yield
0.73%
McKesson stock logo

23. McKesson NYSE:MCK

$734.93 -19.83 (-2.63%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$736.85 +1.92 (+0.26%)
As of 05/8/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $815, which reflects a strong market position and potential for growth.
  • McKesson Co. has received multiple "buy" ratings from analysts, indicating confidence in its future performance.
  • The company reported a significant revenue increase of 11.4% compared to the same quarter last year, showcasing its robust business model.

Cons of McKesson

  • The stock has experienced fluctuations, with a one-year high of $999 and a low of $637, indicating potential volatility.
  • McKesson Co. has a negative return on equity, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Recent insider selling activity could signal a lack of confidence from executives regarding the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$92.45 billion
P/E Ratio
19.10
Consensus Rating
Moderate Buy
Consensus Price Target
$970.73 (+32.1% Upside)
Volume
2.13 million shares
Average Volume
953,588 shares
Today's Range
$726.02
$772.42
50-Day Range
$742.16
$995.05
52-Week Range
$637.00
$999.00
Dividend Yield
0.43%
Boston Scientific stock logo

24. Boston Scientific NYSE:BSX

$53.88 -2.69 (-4.75%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$54.05 +0.16 (+0.30%)
As of 05/8/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $64.95, which presents a potential upside of over 20% based on recent analyst price targets.
  • Boston Scientific Co. has received multiple "buy" ratings from analysts, indicating strong market confidence in the company's growth potential.
  • The company has a solid market capitalization of approximately $96.53 billion, suggesting a stable financial foundation for future growth.

Cons of Boston Scientific

  • Recent guidance cuts for profit and revenue have raised concerns about the company's near-term earnings visibility, leading to increased market skepticism.
  • Multiple analysts have recently slashed their price targets, which can amplify selling pressure and indicate a lack of near-term support for the stock.
  • Legal risks have increased due to several securities-class action notices, which could lead to potential volatility and financial liabilities for the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$84.07 billion
P/E Ratio
22.55
Consensus Rating
Moderate Buy
Consensus Price Target
$93.91 (+74.3% Upside)
Volume
20.83 million shares
Average Volume
18.64 million shares
Today's Range
$53.63
$56.62
50-Day Range
$55.98
$76.68
52-Week Range
$53.63
$109.50
Dividend Yield
N/A
Elevance Health stock logo

25. Elevance Health NYSE:ELV

$377.66 +4.74 (+1.27%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$372.50 -5.16 (-1.37%)
As of 05/8/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$80.98 billion
P/E Ratio
16.06
Consensus Rating
Moderate Buy
Consensus Price Target
$384.58 (+1.8% Upside)
Volume
1.31 million shares
Average Volume
1.69 million shares
Today's Range
$371.09
$379.23
50-Day Range
$280.80
$376.39
52-Week Range
$273.71
$424.24
Dividend Yield
1.84%
Cigna Group stock logo

26. Cigna Group NYSE:CI

$288.01 +3.97 (+1.40%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$284.00 -4.01 (-1.39%)
As of 05/8/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • Analyst sentiment remains largely positive, with multiple buy ratings and a median price target around $334, suggesting potential upside from current levels if the company continues to execute effectively.
  • The Cigna Group's recent earnings report showed a strong performance from its Evernorth unit, which supports durable service-fee revenue, indicating a solid foundation for future growth.
  • The current stock price is approximately $288, which may be seen as an attractive entry point for investors looking for value in the healthcare sector.

Cons of Cigna Group

  • The Cigna Group's decision to exit the Affordable Care Act individual market in 2027 could impact approximately 369,000 members, reducing future premium revenue and potentially alarming investors focused on top-line growth.
  • There are ongoing pressures related to pharmacy benefit management costs, with higher drug prices posing a risk to profit margins if not effectively managed through pricing strategies or cost controls.
  • Recent insider trading activity, including significant stock sales by company insiders, may raise concerns about the confidence of those closest to the company regarding its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$75.14 billion
P/E Ratio
12.21
Consensus Rating
Moderate Buy
Consensus Price Target
$338.35 (+17.5% Upside)
Volume
1.66 million shares
Average Volume
1.63 million shares
Today's Range
$283.80
$288.47
50-Day Range
$257.97
$292.16
52-Week Range
$239.51
$338.89
Dividend Yield
2.20%
Regeneron Pharmaceuticals stock logo

27. Regeneron Pharmaceuticals NASDAQ:REGN

$714.89 +5.79 (+0.82%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$716.40 +1.51 (+0.21%)
As of 05/8/2026 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • Recent analyst upgrades have increased the price target for Regeneron Pharmaceuticals, Inc. to around $995, indicating strong confidence in the stock's potential for growth.
  • The company reported a significant earnings per share (EPS) of $9.47, surpassing expectations, which reflects strong financial performance and operational efficiency.
  • Regeneron Pharmaceuticals, Inc. has a robust pipeline with recent positive developments in its C5 program, suggesting potential for new product launches that could drive future revenue.

Cons of Regeneron Pharmaceuticals

  • There has been a decline in net income, which fell by about 10% despite revenue growth, highlighting potential volatility in profitability.
  • Recent sales of EYLEA, a key product, have not met expectations, and increasing competition in the retina treatment market poses a risk to future sales.
  • Wells Fargo recently lowered its price target for the stock to $800, indicating a more cautious outlook and potential short-term challenges.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$74.97 billion
P/E Ratio
17.42
Consensus Rating
Moderate Buy
Consensus Price Target
$826.59 (+15.6% Upside)
Volume
559,041 shares
Average Volume
755,624 shares
Today's Range
$708.36
$717.99
50-Day Range
$686.36
$790.81
52-Week Range
$476.49
$821.11
Dividend Yield
0.53%
Takeda Pharmaceutical stock logo

28. Takeda Pharmaceutical NYSE:TAK

$16.48 -0.16 (-0.93%)
Closing price 05/8/2026 03:58 PM Eastern
Extended Trading
$16.46 -0.02 (-0.12%)
As of 05/8/2026 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Recent upgrades from analysts, including a shift to a "strong-buy" rating, indicate growing confidence in the company's future performance.
  • The current stock price is around $16.65, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Takeda Pharmaceutical Company Limited has a strong market capitalization of approximately $52.97 billion, suggesting stability and the ability to invest in research and development.

Cons of Takeda Pharmaceutical

  • The company reported a net margin of only 2.58%, which may raise concerns about profitability and operational efficiency.
  • Takeda Pharmaceutical Company Limited missed its earnings expectations in the last quarter, which could signal challenges in meeting future financial targets.
  • With a P/E ratio of 69.36, the stock may be considered overvalued compared to industry peers, potentially limiting upside for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$52.96 billion
P/E Ratio
68.69
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
4.36 million shares
Average Volume
2.68 million shares
Today's Range
$16.46
$16.66
50-Day Range
$16.31
$18.77
52-Week Range
$12.99
$18.90
Dividend Yield
3.03%
Cencora stock logo

29. Cencora NYSE:COR

$261.16 +5.50 (+2.15%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$261.40 +0.24 (+0.09%)
As of 05/8/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $398, reflecting a strong market position and investor confidence.
  • Cencora, Inc. has recently received multiple upgrades from analysts, indicating positive growth expectations and a consensus rating of "Moderate Buy."
  • The company reported a year-over-year revenue increase of 5.5%, showcasing its ability to grow despite market challenges.

Cons of Cencora

  • The company has a relatively high debt-to-equity ratio of 3.62, which may indicate financial risk and reliance on borrowed funds.
  • Despite a positive earnings report, Cencora, Inc. fell short of revenue expectations, which could raise concerns about future performance.
  • The stock has shown volatility, with a beta of 0.72, suggesting it may not be as stable as some investors prefer.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.73 billion
P/E Ratio
20.03
Consensus Rating
Moderate Buy
Consensus Price Target
$388.42 (+48.7% Upside)
Volume
2.67 million shares
Average Volume
1.85 million shares
Today's Range
$254.00
$266.38
50-Day Range
$253.20
$372.90
52-Week Range
$244.82
$377.54
Dividend Yield
0.94%
argenex stock logo

30. argenex NASDAQ:ARGX

$782.17 -5.14 (-0.65%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$797.88 +15.71 (+2.01%)
As of 05/8/2026 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $746, reflecting strong market interest and potential for growth.
  • Argentx SE has a robust pipeline of therapies targeting various autoimmune diseases, including its lead product candidate, efgartigimod, which has shown promise in treating conditions like myasthenia gravis.
  • The company has established strategic partnerships with major firms such as AbbVie and Zai Lab, which can enhance its research capabilities and market reach.

Cons of argenex

  • The stock has experienced volatility, with a fifty-two week high of $934.62 and a low of $510.05, indicating potential risks associated with price fluctuations.
  • Despite its promising pipeline, the biotechnology sector is highly competitive, and there is no guarantee that argenx SE's products will achieve regulatory approval or commercial success.
  • Institutional investors hold a significant portion of the stock, which can lead to increased volatility if large shareholders decide to sell their positions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.96 billion
P/E Ratio
34.83
Consensus Rating
Moderate Buy
Consensus Price Target
$1,017.78 (+30.1% Upside)
Volume
354,205 shares
Average Volume
307,650 shares
Today's Range
$778.13
$792.00
50-Day Range
$663.93
$849.04
52-Week Range
$510.05
$934.62
Dividend Yield
N/A
Edwards Lifesciences stock logo

31. Edwards Lifesciences NYSE:EW

$79.86 -2.90 (-3.51%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$79.94 +0.08 (+0.10%)
As of 05/8/2026 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The company has recently updated its earnings guidance for Q2 2026, projecting earnings per share (EPS) between 0.700 and 0.760, which is in line with market expectations, indicating stable financial performance.
  • Edwards Lifesciences Co. has a strong market capitalization of approximately $48.47 billion, reflecting its significant presence in the medical technology sector.
  • The stock is currently trading around $79.69, which may present a buying opportunity for investors looking for growth in the healthcare sector.

Cons of Edwards Lifesciences

  • The stock has experienced volatility, with a 12-month high of $87.89 and a low of $72.30, indicating potential risks associated with price fluctuations.
  • Despite positive earnings guidance, the company's price-to-earnings (P/E) ratio is relatively high at around 44.72, which may suggest that the stock is overvalued compared to its earnings.
  • Recent analyst reports have shown a downward adjustment in price targets, with some brokerages reducing their expectations, which could signal caution for potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.65 billion
P/E Ratio
42.48
Consensus Rating
Moderate Buy
Consensus Price Target
$95.65 (+19.8% Upside)
Volume
4.03 million shares
Average Volume
5.68 million shares
Today's Range
$79.24
$83.04
50-Day Range
$77.85
$87.27
52-Week Range
$72.30
$87.89
Dividend Yield
N/A
IDEXX Laboratories stock logo

32. IDEXX Laboratories NASDAQ:IDXX

$560.11 -12.09 (-2.11%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$559.98 -0.13 (-0.02%)
As of 05/8/2026 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $589, which reflects a significant increase from its 52-week low, indicating potential for growth.
  • IDEXX Laboratories, Inc. reported a strong quarterly earnings performance, exceeding analysts' expectations with earnings per share of $3.08, showcasing robust financial health.
  • The company has demonstrated a solid revenue growth of 14.3% compared to the same quarter last year, indicating a strong demand for its diagnostic products and services.

Cons of IDEXX Laboratories

  • Insider selling has been notable, with executives selling a significant number of shares, which may raise concerns about their confidence in the company's future performance.
  • The stock has experienced fluctuations, with a recent price drop from its 52-week high, indicating potential volatility that could deter risk-averse investors.
  • Analysts have recently lowered price targets for the stock, which may suggest a more cautious outlook on its near-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.14 billion
P/E Ratio
41.25
Consensus Rating
Moderate Buy
Consensus Price Target
$751.00 (+34.1% Upside)
Volume
476,512 shares
Average Volume
571,407 shares
Today's Range
$555.19
$572.20
50-Day Range
$553.66
$660.71
52-Week Range
$487.30
$769.98
Dividend Yield
N/A
Becton, Dickinson and Company stock logo

33. Becton, Dickinson and Company NYSE:BDX

$149.24 -4.02 (-2.62%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$148.21 -1.03 (-0.69%)
As of 05/8/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $149, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Becton, Dickinson and Company has a strong history of dividend payments, with a recent quarterly dividend of $1.05 per share, translating to an annualized dividend yield of 2.8%. This can provide a steady income stream for investors.
  • The company reported earnings per share of $2.91, exceeding analysts' expectations, indicating strong financial performance and potential for future growth.

Cons of Becton, Dickinson and Company

  • The company’s revenue for the latest quarter was $4.49 billion, which fell short of analysts' expectations, suggesting potential challenges in meeting future growth targets.
  • With a debt-to-equity ratio of 0.67, while manageable, it indicates that the company has a moderate level of debt, which could pose risks in a rising interest rate environment.
  • The stock has experienced volatility, with a one-year high of $187.35 and a low of $127.59, which may concern risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.64 billion
P/E Ratio
37.78
Consensus Rating
Hold
Consensus Price Target
$184.71 (+23.8% Upside)
Volume
4.48 million shares
Average Volume
3.16 million shares
Today's Range
$146.49
$155.28
50-Day Range
$144.15
$180.79
52-Week Range
$127.59
$187.35
Dividend Yield
2.74%
Cardinal Health stock logo

34. Cardinal Health NYSE:CAH

$183.97 -1.31 (-0.71%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$184.69 +0.72 (+0.39%)
As of 05/8/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Recent earnings reports showed that Cardinal Health, Inc. exceeded analysts' expectations for earnings per share, indicating strong financial performance.
  • The current stock price is around $199.74, which may present a buying opportunity for investors looking for growth potential.
  • Analysts have a consensus rating of "Moderate Buy" for Cardinal Health, Inc., suggesting confidence in the company's future performance.

Cons of Cardinal Health

  • Recent revenue reports missed expectations, which could signal potential challenges in meeting future growth targets.
  • GAAP results showed a decline in operating earnings, influenced by a significant goodwill impairment charge, which may raise concerns about profitability.
  • Mixed results in recent earnings reports have led to increased volatility, which could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.39 billion
P/E Ratio
28.13
Consensus Rating
Moderate Buy
Consensus Price Target
$241.80 (+31.4% Upside)
Volume
3.26 million shares
Average Volume
2.00 million shares
Today's Range
$182.87
$190.24
50-Day Range
$185.11
$230.12
52-Week Range
$137.75
$233.60
Dividend Yield
1.10%
Teva Pharmaceutical Industries stock logo

35. Teva Pharmaceutical Industries NYSE:TEVA

$35.71 -0.30 (-0.82%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$35.58 -0.14 (-0.39%)
As of 05/8/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$41.40 billion
P/E Ratio
26.85
Consensus Rating
Moderate Buy
Consensus Price Target
$41.78 (+17.0% Upside)
Volume
8.22 million shares
Average Volume
6.93 million shares
Today's Range
$35.43
$36.33
50-Day Range
$28.37
$36.36
52-Week Range
$14.99
$37.35
Dividend Yield
N/A
Haleon stock logo

36. Haleon NYSE:HLN

$9.12 -0.19 (-1.99%)
Closing price 05/8/2026 03:58 PM Eastern
Extended Trading
$9.24 +0.12 (+1.36%)
As of 05/8/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $9.59, which may present a buying opportunity for investors looking for value in the consumer healthcare sector.
  • Haleon plc has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment and potential for price appreciation.
  • The company recently announced a dividend of $0.1307, reflecting a commitment to returning value to shareholders, with a notable dividend yield.

Cons of Haleon

  • Deutsche Bank downgraded Haleon from a "hold" to a "sell" rating, indicating potential concerns about the company's short-term performance.
  • The stock has experienced fluctuations, with a 12-month low of $8.71, which may raise concerns about its volatility and market perception.
  • Haleon's current ratio of 0.92 suggests that the company may face challenges in meeting its short-term liabilities, which could impact financial stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.38 billion
P/E Ratio
23.37
Consensus Rating
Moderate Buy
Consensus Price Target
$13.40 (+47.0% Upside)
Volume
20.07 million shares
Average Volume
8.15 million shares
Today's Range
$9.07
$9.18
50-Day Range
$9.18
$11.06
52-Week Range
$8.71
$11.42
Dividend Yield
2.68%
Alnylam Pharmaceuticals stock logo

37. Alnylam Pharmaceuticals NASDAQ:ALNY

$295.05 -0.86 (-0.29%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$293.66 -1.39 (-0.47%)
As of 05/8/2026 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The stock has shown resilience with a current price around $308, indicating potential for recovery and growth in the biotech sector.
  • Analysts have a consensus rating of "Moderate Buy" with a target price averaging around $472.78, suggesting significant upside potential.
  • Recent insider transactions indicate confidence in the company, with executives selling shares primarily for tax obligations rather than lack of faith in the company's future.

Cons of Alnylam Pharmaceuticals

  • The stock has experienced volatility, with a 12-month high of $495.55 and a low of $240.00, indicating potential risks associated with price fluctuations.
  • Insider ownership is relatively low at around 0.86%, which may suggest a lack of alignment between management and shareholder interests.
  • Recent analyst downgrades have occurred, with some firms reducing their price targets significantly, reflecting concerns about future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.51 billion
P/E Ratio
80.61
Consensus Rating
Moderate Buy
Consensus Price Target
$471.96 (+60.0% Upside)
Volume
926,759 shares
Average Volume
1.13 million shares
Today's Range
$293.06
$300.17
50-Day Range
$295.91
$339.41
52-Week Range
$250.35
$495.55
Dividend Yield
N/A
Zoetis stock logo

38. Zoetis NYSE:ZTS

$82.80 -4.51 (-5.17%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$82.82 +0.02 (+0.02%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $117, indicating a potential upside of approximately 10.77% based on recent analyst target prices.
  • Zoetis Inc. has shown consistent revenue growth, with a reported increase of 3.0% compared to the same quarter last year, reflecting strong demand for its products.
  • The company has a solid market capitalization of approximately $49.36 billion, which suggests stability and investor confidence.

Cons of Zoetis

  • Recent target price reductions by analysts, such as UBS Group lowering their target from $136 to $130, may indicate concerns about future performance.
  • The company has a relatively high debt-to-equity ratio of 2.71, which could pose risks if market conditions change or if interest rates rise.
  • Despite a strong market presence, Zoetis Inc. has faced rating downgrades from some analysts, which could affect investor confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.73 billion
P/E Ratio
13.73
Consensus Rating
Hold
Consensus Price Target
$141.25 (+70.6% Upside)
Volume
17.18 million shares
Average Volume
4.93 million shares
Today's Range
$81.10
$87.58
50-Day Range
$86.99
$131.06
52-Week Range
$81.10
$172.23
Dividend Yield
2.43%
BeOne Medicines stock logo

39. BeOne Medicines NASDAQ:ONC

$312.12 -4.88 (-1.54%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$305.50 -6.62 (-2.12%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$34.78 billion
P/E Ratio
69.83
Consensus Rating
Moderate Buy
Consensus Price Target
$391.00 (+25.3% Upside)
Volume
210,292 shares
Average Volume
215,343 shares
Today's Range
$311.66
$318.06
50-Day Range
$274.73
$351.92
52-Week Range
$218.31
$385.22
Dividend Yield
N/A
Waters stock logo

40. Waters NYSE:WAT

$355.12 +4.63 (+1.32%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$354.41 -0.71 (-0.20%)
As of 05/8/2026 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$34.41 billion
P/E Ratio
45.12
Consensus Rating
Moderate Buy
Consensus Price Target
$395.12 (+11.3% Upside)
Volume
1.81 million shares
Average Volume
1.08 million shares
Today's Range
$339.15
$356.99
50-Day Range
$283.58
$349.94
52-Week Range
$275.05
$414.15
Dividend Yield
N/A
Agilent Technologies stock logo

41. Agilent Technologies NYSE:A

$115.52 -3.13 (-2.64%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$114.22 -1.30 (-1.12%)
As of 05/8/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $114.84, which may present a buying opportunity for investors looking for growth in the medical research sector.
  • Agilent Technologies, Inc. reported a revenue increase of 7.0% year-over-year, indicating strong business performance and potential for future growth.
  • The company has a solid return on equity of 24.49%, suggesting effective management and profitability, which can be attractive to investors.

Cons of Agilent Technologies

  • The company recently missed earnings expectations by a small margin, which could raise concerns about its ability to meet future financial targets.
  • Agilent Technologies, Inc. has a relatively high P/E ratio of 25.35, which may suggest that the stock is overvalued compared to its earnings.
  • Market volatility, indicated by a beta of 1.30, suggests that the stock may experience larger price fluctuations, which could be risky for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.53 billion
P/E Ratio
25.50
Consensus Rating
Buy
Consensus Price Target
$163.71 (+41.7% Upside)
Volume
2.69 million shares
Average Volume
2.07 million shares
Today's Range
$113.28
$118.11
50-Day Range
$110.35
$124.85
52-Week Range
$106.79
$160.27
Dividend Yield
0.86%
Alcon stock logo

42. Alcon NYSE:ALC

$62.50 -1.38 (-2.15%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$63.03 +0.53 (+0.84%)
As of 05/8/2026 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • Recent analyst ratings have been positive, with multiple firms issuing buy ratings, indicating strong confidence in the company's future performance.
  • The median price target set by analysts for Alcon Inc. is around $94.5, suggesting potential for significant upside from the current stock price.
  • Institutional interest is strong, with numerous investors adding shares to their portfolios, reflecting a positive outlook on the company's growth prospects.

Cons of Alcon

  • Recent hedge fund activity shows some significant sell-offs, with major investors reducing their positions, which could indicate a lack of confidence in the stock's short-term performance.
  • One member of Congress recently sold shares of Alcon Inc., which may raise concerns about insider sentiment regarding the company's future.
  • Despite positive analyst ratings, the stock market can be volatile, and external economic factors could negatively impact Alcon Inc.'s performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.60 billion
P/E Ratio
37.65
Consensus Rating
Moderate Buy
Consensus Price Target
$85.12 (+36.2% Upside)
Volume
4.54 million shares
Average Volume
1.90 million shares
Today's Range
$62.40
$64.82
50-Day Range
$63.88
$87.14
52-Week Range
$62.40
$96.88
Dividend Yield
N/A
Natera stock logo

43. Natera NASDAQ:NTRA

$194.24 -25.58 (-11.64%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$195.23 +0.99 (+0.51%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$31.28 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$256.00 (+31.8% Upside)
Volume
3.92 million shares
Average Volume
1.45 million shares
Today's Range
$192.52
$217.65
50-Day Range
$182.65
$219.82
52-Week Range
$131.81
$256.36
Dividend Yield
N/A
Revolution Medicines stock logo

44. Revolution Medicines NASDAQ:RVMD

$141.81 -0.70 (-0.49%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$141.70 -0.11 (-0.08%)
As of 05/8/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$30.30 billion
P/E Ratio
N/A
Consensus Rating
Buy
Consensus Price Target
$103.88 (-26.8% Downside)
Volume
2.51 million shares
Average Volume
4.76 million shares
Today's Range
$140.53
$144.61
50-Day Range
$92.51
$152.54
52-Week Range
$34.00
$155.70
Dividend Yield
N/A
ResMed stock logo

45. ResMed NYSE:RMD

$206.65 -0.24 (-0.12%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$206.20 -0.45 (-0.22%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The current stock price is around $217, which is significantly lower than its 52-week high, presenting a potential buying opportunity for investors looking for value.
  • ResMed Inc. has shown strong financial performance, with recent quarterly earnings exceeding analysts' expectations, indicating robust operational efficiency and demand for its products.
  • The company has a solid market capitalization of approximately $31.65 billion, reflecting its stability and presence in the medical equipment sector.

Cons of ResMed

  • The stock has recently reached a 52-week low, which may signal underlying issues or market sentiment that could deter potential investors.
  • Recent reports indicate that some institutional investors have reduced their stakes in ResMed Inc., which could reflect a lack of confidence in the company's short-term prospects.
  • Despite positive earnings, the stock has experienced volatility, which may pose risks for investors looking for stable returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.14 billion
P/E Ratio
19.93
Consensus Rating
Moderate Buy
Consensus Price Target
$286.18 (+38.5% Upside)
Volume
993,553 shares
Average Volume
1.34 million shares
Today's Range
$203.92
$207.98
50-Day Range
$206.83
$259.18
52-Week Range
$198.64
$293.81
Dividend Yield
1.16%
IQVIA stock logo

46. IQVIA NYSE:IQV

$178.48 -0.17 (-0.09%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$178.86 +0.39 (+0.22%)
As of 05/8/2026 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The company recently reported earnings per share (EPS) of $3.42, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • IQVIA Holdings Inc. has a robust revenue growth of over 10% year-over-year, reflecting its strong market position and demand for its services in the life sciences sector.
  • With a market capitalization of approximately $27.77 billion, IQVIA Holdings Inc. is well-established, providing stability and confidence for investors.

Cons of IQVIA

  • The stock has a relatively high P/E ratio of 20.82, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Recent analyst ratings have shown some downward adjustments in price targets, which could signal a lack of confidence in short-term performance.
  • With a beta of 1.39, the stock is more volatile than the market, which could lead to higher risk for investors during market fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.82 billion
P/E Ratio
22.12
Consensus Rating
Buy
Consensus Price Target
$225.69 (+26.5% Upside)
Volume
1.08 million shares
Average Volume
1.75 million shares
Today's Range
$175.28
$182.62
50-Day Range
$156.42
$179.09
52-Week Range
$134.65
$247.04
Dividend Yield
N/A
Humana stock logo

47. Humana NYSE:HUM

$274.58 +27.46 (+11.11%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$271.06 -3.51 (-1.28%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • Recent analyst upgrades have raised the price target for Humana Inc. to around $255, indicating a potential upside from the current stock price of approximately $235.
  • Humana Inc. has a strong market presence in the Medicare Advantage sector, which is expected to grow as the population ages, providing a stable revenue stream.
  • The company has reported a solid financial performance, with a market cap of $28.25 billion and a PE ratio that suggests growth potential compared to industry averages.

Cons of Humana

  • Management has indicated that Medicare payment updates are not keeping pace with rising costs, which could lead to margin pressures and affect profitability.
  • Despite recent earnings beats, the stock has faced downward pressure due to unchanged guidance and concerns over declining MA Star ratings, which impact quality bonuses.
  • There are mixed views among analysts regarding the company's growth potential versus near-term risks, reflected in the high number of "Hold" ratings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.67 billion
P/E Ratio
29.37
Consensus Rating
Hold
Consensus Price Target
$247.61 (-9.8% Downside)
Volume
3.15 million shares
Average Volume
1.72 million shares
Today's Range
$247.50
$274.97
50-Day Range
$163.80
$247.28
52-Week Range
$163.11
$315.35
Dividend Yield
1.43%
Royalty Pharma stock logo

48. Royalty Pharma NASDAQ:RPRX

$50.79 +0.59 (+1.18%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$50.52 -0.27 (-0.52%)
As of 05/8/2026 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The current stock price is around $49.56, reflecting a stable market position and potential for growth.
  • Royalty Pharma plc has a strong dividend yield of approximately 1.9%, providing investors with regular income from their investments.
  • Analysts have recently upgraded their ratings on the stock, with several firms issuing "buy" ratings, indicating positive market sentiment.

Cons of Royalty Pharma

  • The stock has experienced a slight decline of about 0.3% recently, which may indicate short-term volatility.
  • Royalty Pharma plc has a relatively high price-to-earnings (P/E) ratio of 36.67, suggesting that the stock may be overvalued compared to its earnings.
  • The company has a debt-to-equity ratio of 0.88, which, while manageable, indicates that it relies on debt financing to some extent, posing potential risks in economic downturns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.96 billion
P/E Ratio
34.55
Consensus Rating
Buy
Consensus Price Target
$53.71 (+5.8% Upside)
Volume
3.76 million shares
Average Volume
3.26 million shares
Today's Range
$50.50
$51.17
50-Day Range
$45.15
$50.77
52-Week Range
$32.15
$51.65
Dividend Yield
1.87%
Biogen stock logo

49. Biogen NASDAQ:BIIB

$193.45 +2.07 (+1.08%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$192.88 -0.57 (-0.30%)
As of 05/8/2026 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More about Biogen

Pros of Biogen

  • Recent analyst upgrades have increased price targets for Biogen Inc., with some analysts setting targets as high as $275, indicating potential for significant upside.
  • The current stock price is around $182, which may present a buying opportunity for investors looking for value in the biotechnology sector.
  • Biogen Inc. has a strong focus on neurological therapies, which are in high demand, particularly in areas like Alzheimer's disease and multiple sclerosis.

Cons of Biogen

  • Short interest in Biogen Inc. has risen significantly, indicating that more investors are betting against the stock, which could lead to downward pressure on its price.
  • Recent earnings estimates have been trimmed by analysts, suggesting potential risks to near-term earnings expectations, which could negatively impact investor sentiment.
  • Despite some positive ratings, there is still a notable number of analysts who have assigned a "Hold" or "Reduce" rating, indicating caution among market experts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.25 billion
P/E Ratio
20.76
Consensus Rating
Moderate Buy
Consensus Price Target
$214.23 (+10.7% Upside)
Volume
931,535 shares
Average Volume
1.15 million shares
Today's Range
$189.50
$195.20
50-Day Range
$172.34
$194.38
52-Week Range
$118.05
$202.41
Dividend Yield
N/A
GE HealthCare Technologies stock logo

50. GE HealthCare Technologies NASDAQ:GEHC

$63.47 +2.13 (+3.47%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$63.50 +0.03 (+0.05%)
As of 05/8/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company has shown topline strength, indicating a solid growth story that could lead to increased revenues and profitability.
  • Recent operational updates include the strategic combination of Imaging and Advanced Visualization Solutions into Advanced Imaging Solutions, which may enhance efficiency and innovation over time.
  • Insider buying activity has been noted, with key executives purchasing shares at around $60.45, suggesting confidence in the company's future performance.

Cons of GE HealthCare Technologies

  • Recent guidance cuts have lowered FY26 EPS expectations to $4.80–5.00, which is below consensus estimates, reflecting potential challenges in meeting financial targets.
  • Margin pressure has been cited due to inflation and rising costs related to chips, oil, and freight, which could impact profitability in the near term.
  • Analyst downgrades from firms like JPMorgan and Citigroup, with price targets cut from $80 to $65, indicate lowered expectations and could lead to further stock price declines.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.90 billion
P/E Ratio
15.18
Consensus Rating
Hold
Consensus Price Target
$80.67 (+27.1% Upside)
Volume
8.36 million shares
Average Volume
5.61 million shares
Today's Range
$62.00
$63.49
50-Day Range
$59.49
$84.27
52-Week Range
$58.75
$89.77
Dividend Yield
0.23%